GMRE vs DOC

For growth investors, Healthpeak Properties, Inc.

(DOC) is the stronger pick with 4. 5% revenue growth year-over-year, versus -1. 8% for Global Medical REIT Inc. (GMRE). Global Medical REIT Inc. (GMRE) offers the better valuation at 115. 3x trailing P/E (595. 7x forward), making it the more compelling value choice. Analysts rate Global Medical REIT Inc. (GMRE) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Global Medical REIT Inc.

(GMRE) is the cheapest at 115. 3x versus Healthpeak Properties, Inc. at 195. 0x. On forward P/E, Healthpeak Properties, Inc. is actually cheaper at 100. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Healthpeak Properties, Inc.

(DOC) delivered a total return of -16. 1%, compared to -19. 8% for Global Medical REIT Inc. (GMRE). Over 10 years, the gap is even starker: GMRE returned +308. 1% versus DOC's +15. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Global Medical REIT Inc.

(GMRE) is the lower-risk stock at 0. 48β versus Healthpeak Properties, Inc. 's 0. 52β — meaning DOC is approximately 8% more volatile than GMRE relative to the S&P 500. On balance sheet safety, Global Medical REIT Inc. (GMRE) carries a lower debt/equity ratio of 118% versus 126% for Healthpeak Properties, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Healthpeak Properties, Inc.

(DOC) is pulling ahead at 4. 5% versus -1. 8% for Global Medical REIT Inc. (GMRE). On earnings-per-share growth, the picture is similar: Healthpeak Properties, Inc. grew EPS -72. 2% year-over-year, compared to -94. 6% for Global Medical REIT Inc.. Over a 3-year CAGR, DOC leads at 11. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Global Medical REIT Inc.

(GMRE) is the more profitable company, earning 4. 8% net margin versus 2. 5% for Healthpeak Properties, Inc. — meaning it keeps 4. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMRE leads at 23. 6% versus 19. 3% for DOC. At the gross margin level — before operating expenses — GMRE leads at 78. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Healthpeak Properties, Inc.

(DOC) trades at 100. 1x forward P/E versus 595. 7x for Global Medical REIT Inc. — 495. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMRE: 11. 9% to $40. 00.

All stocks in this comparison pay dividends.

Global Medical REIT Inc. (GMRE) offers the highest yield at 63. 5%, versus 6. 3% for Healthpeak Properties, Inc. (DOC).

For long-horizon retirement investors, Global Medical REIT Inc.

(GMRE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), 63. 5% yield, +308. 1% 10Y return). Both have compounded well over 10 years (GMRE: +308. 1%, DOC: +15. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.